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Abstract: T-lymphocytes have the potential to recognize cancer antigens as foreign and 
therefore eliminate them. However, immune checkpoints such as cytotoxic T-lymphocyte-
associated antigen (CTLA)-4 and programmed cell death (PD)-1 receptor and its ligands 
(PD-L1, PD-L2) suppress the activity of T-lymphocytes. Advances in the understanding of 
immunology and its role in cancer have led to the development of immune checkpoint 
inhibitors that block CTLA-4 and PD-1 and result in durable responses in patients with a 
wide range of cancers. PD-1 and PD-L1 inhibitors are currently in many stages of clinical 
investigation, and the anti-PD-1 antibody, pembrolizumab, was recently approved by the US 
Food and Drug Administration. Many questions remain to be answered, such as the optimal 
administration schedule, biomarkers that associate with benefit, and potential for use of 
PD-1 agents in combination approaches. Nonetheless, immunotherapy with PD-1 blocking 
antibodies is now becoming an integral part in the management of cancer.
Keyword: immune checkpoints, immunotherapy, programmed cell death protein-1, cytotoxic 
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Immunology and cancer
Activation of the immune system is recognized as an important treatment strategy 
against cancer.1 Cancer is characterized by genetic mutations and alterations in cel-
lular regulatory processes that can lead to the expression of various tumor-related 
antigens. These antigens can be presented to cytotoxic T-lymphocytes by way of 
antigen-presenting cells (APCs). One role of T-lymphocytes is to differentiate between 
“self” and “non-self” antigens and aid in the removal of “non-self” antigens without 
over-activating the immune system and causing damage to “self” antigens.2 Therefore, 
T-lymphocytes have the potential to recognize cancer-related antigens as “non-self” 
and eradicate these cancer cells.3 The immune response against cancer occurs in three 
stages, known as the three ‘E’s: elimination, equilibrium, and escape.4,5 The goal is 
elimination of cancer cells by the immune system; however, when complete elimina-
tion cannot be attained, persistent activation of the immune system can maintain a 
state of equilibrium. Escape is the state of cancer growth, when a tumor cell has been 
successful in evading immune destruction.
A series of steps must be carried out in order for an effective immune response 
against cancer to occur. First, the tumor-related antigen must be picked up and pro-
cessed by the APC. APCs include macrophages, B-lymphocytes, and dendritic cells. 
Of these, dendritic cells are the most effective, as their dendrites increase their ability 
to capture antigens for presentation.6 APCs travel to the lymph node to present the 
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processed antigen bound to major histocompatibility com-
plex (MHC) molecules to the T-lymphocytes. To activate and 
prime the T-cell for its effector phase (ie, to respond against 
the cancer-related antigens), two signals need to occur. The 
first signal is the binding of the T-cell receptor (TCR) to the 
MHC-bound antigen. Simultaneously, a second signal involv-
ing the interaction between co-stimulatory molecules, such as 
B7 on activated APCs and cluster of differentiation (CD)-28 
expressed on T-lymphocytes, occurs, and the combination of 
these two signals allow for the proliferation and activation 
of T-lymphocytes.
With this immunologic framework in mind, historically, 
several immunotherapeutic agents have been used in can-
cer therapy, including cancer vaccines and cytokines such 
as interferon-alpha and interleukin (IL)-2. Though there 
have been some successes in cancer vaccine development 
such as the FDA approval of sipuleucel-T,7 generally the 
efficacy of therapeutic cancer vaccines is felt to be   modest.8 
Interferon-alpha and IL-2 have also shown modest benefit. 
Interferon-alpha is the only FDA-approved agent for the 
adjuvant treatment of melanoma. This approval was based 
on initial data that showed an improvement in relapse-
free survival (RFS) and overall survival (OS); however, 
subsequent studies confirmed an improvement in RFS but 
not necessarily in OS.9,10 IL-2 is approved for treatment of 
metastatic melanoma. Response rates to IL-2 range from 
16% to 23%, and 5%–10% of patients achieve profound, 
durable benefits. Nevertheless, both interferon-alpha and 
IL-2 are associated with toxicity, and better therapies that 
help more patients are needed.11,12
It is possible that prior immunotherapeutic approaches 
such as vaccines and cytokines had only limited success 
due to the high level of immunosuppressive networks 
involved in patients with cancer that overpowered these 
prior attempts at enhancing anti-tumor immunity. A greater 
understanding of immune activation, particularly T-lympho-
cyte activation, has now identified multiple co-stimulatory 
and co-inhibitory pathways that regulate this process.6 One 
important mechanism relevant to immunotherapy are the 
co-inhibitory receptors such as cytotoxic T-lymphocyte-
associated antigen (CTLA)-4 and programmed cell death 
1 (PD-1) receptor.6 These co-inhibitory molecules serve 
to dampen the immune response to maintain immunologic 
homeostasis. During antigen presentation, T-lymphocytes 
are also affected by the microenvironment, thus the 
immune response generated is a result of several factors, 
including stimulation and inhibition in the context of the 
microenvironment.3,6
Cancers have many ways of evading and thus escaping 
an otherwise effective immune response. Tumor-related 
antigens may not be properly presented, antigens may be 
recognized as “self” and induce anergy, T-lymphocytes may 
not be appropriately activated, or T-lymphocytes may be 
excessively inhibited.3
Cytotoxic T -lymphocyte antigen 4 
as the prototypical immunologic 
checkpoint
In order to maintain immune homeostasis and avoid compli-
cations from immune over-activation, several mechanisms of 
negative regulation are put in place. One such mechanism 
involves immune checkpoints, which include the receptors 
CTLA-4 and PD-1, receptors that are expressed on the 
T-lymphocyte surface. Tumor cells are capable of resisting 
the immune system by expressing ligands such as PD-L1 or 
PD-L2, which interact with the PD-1 receptor to suppress 
immunity.3,13
CTLA-4 (also known as CD152) and PD-1 (also known 
as CD279) were the first two immune checkpoints to be 
evaluated extensively in the setting of clinical cancer 
  immunotherapy. They differ in the manner and level at which 
they negatively regulate the immune system (Figure 1).13
CTLA-4 was the first immune checkpoint receptor to 
be targeted by a therapeutic agent. It is expressed only on 
T-lymphocytes, and it negatively regulates T-lymphocyte 
activation by competing with the co-stimulatory molecule 
CD28 in binding the ligands B7.1 (also known as CD80) and 
B7.2 (also known as CD86). CTLA-4 has a greater affinity 
for these ligands and is also capable of independently send-
ing inhibitory signals to the T-lymphocyte.14–16 Pre-clinical 
models of CTLA-4 blockade showed an anti-tumor immune 
response.17,18
In contrast to CTLA-4, which regulates T-lymphocytes 
at the level of initial activation, PD-1 regulates immunity 
at multiple phases of the immune response, including 
exerting its effect on effector T-lymphocyte activity in the 
peripheral tissues.
Programmed cell death receptors 
as another critical immunologic 
checkpoint
In addition to its activity in cancer immunotherapy, PD-1 has 
been shown to play a role in allergy, autoimmunity, infec-
tious disease, and transplantation immunity.2 PD-1 is highly 
expressed on tumor-infiltrating lymphocytes (TILs) in the Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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effector phase and serves to inhibit T-lymphocyte activity 
during chronic antigen exposure when it is engaged by its 
ligands. Tumor cells monopolize on this immune-resistance 
mechanism. In peripheral tissues, tumor cells and other cells 
in the tumor microenvironment express PD-1 ligands, which 
are believed to protect the tumor cells from immune destruc-
tion (Figure 1).11,19
PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also 
known as B7-DC or CD273) are the two ligands for PD-1. 
When one of the PD-1 ligands engages the PD-1 receptor, 
the ligand/receptor interaction dampens the T-lymphocyte 
response in several ways. It inhibits the kinases involved in 
T-lymphocyte activation via phosphatase activity and other 
signaling pathways.20 Although it predominately regulates 
T-lymphocyte effector activity distally in the tissue and 
tumors, data from   PD-1-deficient T-lymphocytes suggest 
that PD-1 likely plays a role at multiple steps in the immune 
response.21 In addition, PD-1 is expressed on other activated 
cells, including B-lymphocytes and natural killer (NK) 
cells.13 Lastly, chronic antigen exposure can lead to persistent 
PD-1 expression. Enhanced PD-1 expression via chronic 
antigen exposure can therefore both change the duration of 
T-lymphocyte/APC interaction and can lead to T-lymphocyte 
anergy or exhaustion.13,22
As noted above, PD-1 is expressed on TILs from 
many types of cancers. PD-1 ligands are also expressed 
on different types of tumors. PD-L1 is most commonly 
expressed on solid tumors, including melanoma, ovarian, 
lung, and renal carcinomas.23 PD-L2 has been reported to be 
upregulated in different types of lymphoma.24 Pre-clinical 
data have shown that deliberate expression of PD-L1 
on mouse tumor cells inhibits anti-tumor T-lymphocyte 
response.13,23 Yet analysis by immunohistochemistry (IHC) 
or flow cytometry has shown that PD-L1 level expression 
on tumor cells is variable and reasons for its heterogeneity 
are multifactorial.25
Mechanisms that regulate tumor cell PD-L1 expres-
sion include the ‘innate immune resistance’ and the 
‘adaptive immune resistance’ mechanisms. The innate 
  immune-resistance mechanism describes tumor cell PD-L1 
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Figure 1 Simplified concept of CTLA-4 and PD-1 immune checkpoints.
Notes: In the priming phase, antigen-presenting cells present antigens to the T-cell. Two signals are required to initiate a T-cell response. CTLA-4 is upregulated after T-cell 
activation and inhibits the T-cell response. Anti-CTLA-4 antibodies bind to CTLA-4, turning off the ‘inhibitory signal’, thus resulting in an enhancement of T-cell function. In 
the effector phase, the PD-1 inhibitory receptor is expressed by the T-cell and, when it is engaged by its ligands PD-L1 and PD-L2, it serves to inhibit the T-cell response. 
Anti-PD-1 antibodies bind to PD-1, turning off the ‘inhibitory signal’ in the peripheral tissues and enhancing T-cell function. PD-1/PD-L1 interactions are complex, and this 
interaction is also involved in the priming phase. We have chosen to portray the main concepts for both of these immunologic checkpoints in this figure for simplicity.
Abbreviations: CD, cluster of differentiation; CTLA, cytotoxic T-lymphocyte-associated antigen; MHC, major histocompatibility complex; PD, programmed cell death; 
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expression that may be related to oncogenic signaling 
pathways inherent in the tumor cell. This mechanism does 
not depend on inflammatory signals in the microenviron-
ment. One example of innate immune resistance includes 
constitutive anaplastic lymphoma kinase (ALK) signaling in 
lung cancer that has been reported to drive PD-L1 expres-
sion through signal transducer and activator of transcription 
(STAT)-3 signaling.26,27,28
The adaptive immune-resistance mechanism describes 
tumor cell PD-L1 expression that is induced in response to 
immune activity within the tumor microenvironment, thereby 
leading to a non-uniform expression of PD-L1.29 With adap-
tive immune resistance, the tumor cells take advantage of 
the PD-1/PD-L1interaction that under normal circumstances 
protects cells from immune-mediated harm. Inflammatory 
signals (such as interferons) produced by an active antitumor 
immune response in the tumor microenvironment can lead 
to increased expression of PD-L1, which in turn protects 
the tumor cell by then inhibiting that very same antitumor 
response.13,25
Immune checkpoint inhibitors
A greater understanding of immune checkpoints led to the 
development of several immune checkpoint inhibitors. 
  Ipilimumab (trade name Yervoy®), an anti-CTLA-4 mono-
clonal antibody, was the first agent to demonstrate a survival 
benefit in patients with metastatic cutaneous melanoma and 
gained FDA approval in 2011.
Clinical trials with ipilimumab showed a modest 
response rate of 10%–15% at the expense of ipilimumab 
immune-related adverse events (most commonly colitis 
and dermatitis). However two Phase III trials showed that 
ipilimumab improves OS. The median OS rate for patients 
treated with ipilimumab was prolonged compared with 
patients receiving a gp100 cancer vaccine (median OS 10.9 
versus 6.4 months), and patients treated with ipilimumab 
and dacarbazine chemotherapy had improved OS compared 
with those treated with dacarbazine alone (median OS 11.2 
versus 9.1 months).30,31
Patients who achieved a response were often found to 
have a durable response, lasting 1.5–2 years, and 18% of 
patients treated with ipilimumab survived beyond 2 years, 
some patients even many years longer.30–32 In addition, the 
kinetics of response to immunotherapy differs as compared 
with targeted therapy or chemotherapy. Many different 
radiographic patterns may be seen after ipilimumab. On 
occasion, responses to ipilimumab can be delayed, sometimes 
not occurring until 6 months following initiation of therapy. 
Other times, the tumor burden appears to have increased on 
initial imaging but then ultimately may subsequently regress. 
These differences in response kinetics led to the consider-
ation and subsequent development of the immune-related 
response criteria as a method for monitoring response to 
immunotherapy.33
The majority of ipilimumab-related adverse events are 
immune related, and the most common observed side effects 
include diarrhea, colitis, and dermatitis. Less common 
severe immune-related adverse events include hypophysitis, 
thyroiditis, and hepatitis. In the Phase III trial of ipilimumab 
with or without gp100 peptide vaccine compared with gp100 
peptide vaccine alone, immune-related adverse events were 
noted in 60% of patients treated with ipilimumab, and grade 
3 and grade 4 immune-related adverse events occurred in 
10%–15% of these patients.30
The therapeutic benefit achieved with CTLA-4 blockade 
led to the effort in identifying other potential immune check-
point inhibitors – inhibitors that would be more specific, 
equally efficacious, and have less immune toxicity.3 Given that 
PD-1 and PD-L1 are often thought to be more distal immune 
modulators, PD-1 and PD-L1 inhibitors were identified as 
potentially fulfilling those needs. Although agents against 
PD-1 or PD-L1 (Table 1) are not yet FDA approved, they are 
currently in clinical trials, with promising results including 
high objective durable response rates (ORR) and a favor-
able side effect profile.34
Table 1   PD-1  and  PD-L1  therapeutic  agents  in  clinical 
developmenta
Therapeutic agent Target Disease type
Nivolumab (BMS-936558;  
MDX-1106; Bristol-Myers  
Squibb)
PD-1 Solid tumors, melanoma, 
NSCLC, RCC, ovarian
Pembrolizumabb (MK3475;  
formerly lambrolizumab;  
Merck, Keytruda®)
PD-1 Melanomab, NSCLC, head 
and neck
Pidilizumab (CT-011) PD-1 Hematologic malignancies
AMP-224 (Amplimmune/GSK) PD-1 Solid tumors
MDX-1105 (BMS936559) PD-L1 Solid tumors
MPDL3280A (Genentech) PD-L1 Solid tumors, melanoma, 
NSCLC, bladder
MeDi4736 (Medimmune) PD-L1 Solid tumors, melanoma, 
head and neck, gastric
MSB0010718C (eMD Serono) PD-L1 Solid tumors
Notes: aAs of 8 September 2014. List is not exhaustive due to the rapidly changing 
clinical  trial  landscape;  bpembrolizumab  gained  FDA  approval  for  patients  with 
advanced or unresectable melanoma on 4 September 2014.
Abbreviations: FDA, US Food and Drug Administration; NSCLC, non-small cell 
lung cancer; PD, programmed cell death; RCC, renal cell carcinoma.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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Clinical potential of anti-PD-1  
and anti-PD-L1 antibodies
Although PD-1- and PD-L1-directed therapy is currently 
undergoing investigation in several types of malignancy, 
including both solid tumors and hematologic malignan-
cies, PD-1 and PD-L1 therapy has been most studied in 
patients with metastatic melanoma. Antibodies targeting 
PD-1 in clinical development include nivolumab (Opdivo), 
pembrolizumab (also known as MK-3475, formerly lam-
brolizumab), and pidilizumab (CT-011). Of these, nivolumab 
and pembrolizumab have been most extensively studied 
in patients with solid tumors.
The first antibody to target PD-L1 in clinical trials was 
MDX-1105. Antibodies currently in clinical development 
that target PD-L1 include MPDL3280A (Genentech), 
MEDI4736 (MedImmune), and MSB0010718C (EMD Serono). 
Lastly, novel approaches such as AMP-224 (Amplimmune), 
a PD-1 decoy, are also under investigation.
Nivolumab
The first-in-human Phase I study of PD-1 monotherapy with 
nivolumab (Opdivo, formerly BMS936558; MDX1106) was 
conducted in patients with refractory solid tumors.35 One 
durable complete response (CR) was seen in a patient with 
colorectal cancer. Two partial responses (PRs) were also seen 
(one in a patient with melanoma and the other in a patient 
with renal cell carcinoma).
A subsequent Phase I trial investigated the safety and 
activity of nivolumab in 296 patients with pre-treated 
advanced melanoma (n=104), non-small cell lung cancer 
(NSCLC) (n=122), castration-resistant prostate cancer 
(n=17), renal cell cancer (n=34), or colorectal cancer (n=19). 
Data from this study showed that objective responses were 
seen in advanced melanoma (ORR 28%), renal cell cancer 
(ORR 27%), and NSCLC (ORR 18%).36 Durable objective 
responses were noted in 20/31 (65%) of patients lasting 
$1 year. For patients with advanced melanoma, durable 
responses of $1 year were noted in 13/18 (72%) who received 
nivolumab for more than 1 year and stable disease that lasted 
$24 weeks was noted in 6/94 patients. A follow-up analysis 
of this trial in patients with melanoma was notable for an 
ORR of 31%, a median duration of response of 2 years, and 
a median OS of 16.8 months for all dose cohorts (with 1- and 
2-year survival rates of 62% and 43%, respectively) and 20.3 
months at the 3 mg/kg dose.37
Common treatment-related adverse events included 
fatigue, diarrhea, pruritus, rash, nausea, and decreased 
appetite. Grade 3 or 4 treatment-related adverse events 
were seen in 14% of patients. Treatment-related serious 
adverse events were noted in 11% of patients and included 
pneumonitis (3%, and grade 3 or 4 in 1%), colitis, hepatitis, 
thyroiditis, and hypophysitis.36
Another Phase I study looked at safety and efficacy 
of nivolumab with a vaccine in ipilimumab-refractory or 
ipilimumab-naïve patients with melanoma.38 The ORR was 
25% for both groups of patients. The median duration of 
response was not reached at the median 8.1-month follow-up, 
and some responses lasted up to 140 weeks. Lastly, in this 
study, 12 of the 18 ipilimumab-naïve patients who progressed 
on nivolumab were subsequently treated with ipilimumab. 
Two of the 12 patients experienced a PR, and two patients 
had a mixed response, suggesting that patients who progress 
on PD-1 may still respond to CTLA-4 blockade. This is 
consistent with findings in another study where patients who 
progressed on prior ipilimumab were found to still respond 
to nivolumab.38,39
Pembrolizumab
A Phase I trial investigated the safety and tumor response 
with pembrolizumab (MK-3475, formerly lambrolizumab, 
Keytruda®) in patients with both pre-treated and treatment-
naïve advanced melanoma.40 A total of 135 patients were 
treated, and the ORR confirmed across all dose cohorts 
irrespective of prior treatment was 38%, with the highest 
confirmed ORR of 52% in the 10 mg/kg cohort. As with 
nivolumab, responses were durable (11 months at median 
follow-up), and 81% of patients who had a response were 
still receiving treatment at the time of data analysis.
In this study, 79% of patients reported drug-related 
adverse events of any kind (primarily low grade), and 
13% of patients reported grade 3 or 4 drug-related adverse 
events. Grade 3 or 4 adverse events included hypothyroid-
ism, diarrhea, abdominal pain, fatigue, decreased appetite, 
transaminitis, renal failure, rash, and pruritus. In regards to 
immune-related adverse events, pneumonitis was noted in 
4% (all below grade 3), grade 3 or 4 transaminitis in 1%, 
grade 3 nephritis in 1%, grade 3 hyperthyroidism in 1%, 
grade 2 adrenal insufficiency in 1%, and hypothyroidism in 
1%.   Diarrhea was reported in 20% of the patients; however, 
only one case was grade 3. Pembrolizumab has also been 
extensively evaluated in patients with NSCLC, but no pub-
lished results are yet available. Pembrolizumab was recently 
FDA approved for patients with advanced or unresectable 
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Pidilizumab (CT-011)
A Phase I trial evaluated the safety and pharmacokinetics 
of pidilizumab (CT-011) in 17 patients with advanced acute 
myeloid leukemia, chronic lymphocytic leukemia, non-
Hodgkin’s lymphoma, Hodgkin’s lymphoma, and multiple 
myeloma who had progressed despite chemotherapy or stem 
cell transplantation.41 This study showed that pidilizumab was 
safe, well tolerated, and clinical benefit was demonstrated in 
33% of patients.
Subsequently, pidilizumab has been investigated in two 
Phase II trials in patients with hematologic malignancies. The 
first was an international Phase II trial that evaluated pidili-
zumab following autologous hematopoietic stem-cell trans-
plantation (AHSCT) for diffuse large B-cell   lymphoma.42 
A total of 66 patients were treated. In 35 patients who had 
measurable disease after AHSCT and received pidilizumab, 
the ORR was 51% (34% CR and 17% PR). The PFS was 
0.72 at 16 months following the first treatment. Neutropenia 
(19%) and thrombocytopenia (8%) were the most frequent 
grade 3 or 4 toxicity reported; 4% of patients experienced a 
related serious adverse event.42
The second Phase II study evaluated the safety and 
activity of pidilizumab in combination with rituximab in 
patients with relapsed follicular lymphoma.43 32 patients were 
enrolled, and the median follow-up was 15.4 months. The 
study’s primary endpoint was objective response, for which 
29 patients were evaluable. An objective response was noted 
in 66% (19/26) of patients, with 52% CR and 14% PR. The 
combination of pidilizumab and rituximab was well toler-
ated, with no immune-related adverse events or grade 3 or 4 
treatment-related events.
MDX-1105
A multicenter Phase I study of the anti-PD-L1 agent, 
MDX-1105, was investigated in patients with advanced 
solid tumors: melanoma (n=55), NSCLC (n=75), colorectal 
cancer (n=18), renal cell carcinoma (n=17), ovarian cancer 
(n=17), pancreatic cancer (n=14), gastric cancer (n=7), and 
breast cancer (n=4).19 Amongst these disease types, an objec-
tive response was noted in 17% of melanoma, 12% of renal 
cell carcinoma, 10% of NSCLC, and 5% of ovarian cancer 
patients. In patients with at least 1 year follow-up, 50% (8/16) 
had a durable response lasting $1 year.19 The most common 
treatment-related adverse events were diarrhea, arthralgia, 
fatigue, rash, nausea, pruritus, and headache, a majority of 
which were low grade. Grade 3 or 4 treatment-related toxici-
ties were noted in 9% of patients. A total of 39% of patients 
experienced a possible immune-related adverse event, which 
included rash, hypothyroidism, hepatitis, endophthalmitis, 
diabetes mellitus, myasthenia gravis, and one case of 
  sarcoidosis. Though clinical development of MDX-1105 is 
no longer continuing as monotherapy, this clinical experience 
was the first published evidence on the potential benefits of 
PD-L1 blockade.
MPDL3280A (Genentech), MEDI4736 
(Medimmune), MSB0010718C (eMD 
Serono), and AMP-224 (Amplimmune/
GlaxoSmithKline)
Other anti-PD-L1 agents currently in Phase I clinical trials 
include MPDL3280A, MEDI4736, and MSB0010718C.
In a Phase I MPDL3280A trial, an expansion cohort of 
38 patients with metastatic melanoma has thus far shown an 
ORR of 29%, with a 24-week PFS of 43%.44 This agent has 
also been studied in patients with NSCLC and renal cancer, 
and the Phase I expansion cohort of 52 NSCLC patients and 
55 patients with renal cancer showed an ORR of 22% and 
13%, respectively.45,46
MEDI4736 is also being investigated in patients with 
NSCLC, gastric, and head and neck cancers, in whom 
responses have been seen. MSB0010718C is also currently 
in early phase clinical trials in solid tumors.47–49
AMP-224 is a recombinant B7-DC-Fc fusion protein that 
modulates the PD-1 axis by depleting PD-1 high expressing 
effector T-cells. The hypothesis is that this decoy removes the 
exhausted T-cells, allowing the functional effector T-cells to 
restore immune function. The potential benefit of this novel 
mechanism of action is still under investigation.50
Combination therapies
To improve the number of patients who benefit from immu-
notherapy with PD-1/PD-L1 agents, combinations with other 
immunotherapy and standard anticancer treatments have been 
pursued. The combination of nivolumab and ipilimumab was 
investigated in a Phase I trial.39 The concurrent administration 
of both agents showed a manageable side effect profile and 
resulted in an ORR of ∼40% across all dose level cohorts, with 
a duration of response ranging from 6 to 72 weeks at the time 
of publication.39 Immune-related toxicities were numerically 
greater with the combination therapy: grade 3 or 4 adverse 
events were noted in 53% of patients, but many of these 
grade 3/4 toxicities were asymptomatic laboratory toxicities 
of uncertain clinical relevance, such as elevated lipase values 
without associated symptoms of pancreatitis. Although the 
combination of nivolumab and ipilimumab has been the most 
extensively reported PD-1/PD-L1 combination study thus Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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far, ongoing trials are combining PD-1/PD-L1 agents with 
small-molecule targeted therapy, chemotherapy, and vaccines 
in a variety of tumor types and disease settings.
Re-treatment with anti-CTLA-4  
or PD-1 blockade
Although responses to both CTLA-4 and PD-1 blockade can 
be durable, some patients ultimately develop progressive 
disease. Though the reasons for ultimate progression in these 
patients are unclear, one theory suggests that ‘immunoediting’ 
can occur, wherein persistent immune response can change 
the phenotype of the tumor to make it less   immunogenic.51 
Re-treatment or a re-challenge with immunotherapy in this 
setting can in theory potentiate the immune response to rec-
ognize the more ‘edited’ or progressive tumor.51
Clinical data support re-treating select patients with 
immunologic checkpoint-blocking antibodies, such as those 
that target CTLA-4 and PD-1. Some patients who initially 
had an objective response or stable disease to ipilimumab 
but ultimately progressed were re-treated with ipilimumab as 
part of the Phase III trial of ipilimumab plus gp100 vaccine 
versus ipilimumab alone versus gp100 vaccine alone.51 Of 
the 31 re-treatment-eligible patients in the two ipilimumab-
containing arms of the trial, the best ORR to re-treatment 
was 3/23 (13%) in the ipilimumab plus gp100 vaccine and 
3/8 (37.5%) in the ipilimumab-alone groups.
Successful re-treatment has also been reported with 
anti-PD-1 therapy. One publication reported a patient with 
metastatic melanoma who was treated on a Phase I nivolumab 
trial35 who initially experienced a PR that lasted for months 
after discontinuing treatment but eventually had progressive 
disease. This patient received re-treatment with nivolumab 
that resulted in regaining a PR that lasted 16 additional 
months at the time of publication.52 The experience with both 
CTLA-4 and PD-1 re-treatment indicates that re-treatment 
with antibodies that target CTLA-4 and PD-1 is a reasonable 
option for patients who had some initial benefit with treatment 
and no significant toxicities.
PD-L1 expression:  
a dynamic biomarker
There has been great interest in finding biomarkers that can 
help identify which patients would benefit most from anti-
PD-1/PD-L1 therapy. PD-L1 expression on tumor cells as 
detected by immunohistochemical staining has been most 
extensively studied.
Interest in PD-L1 as a biomarker began after the first cor-
relation between PD-L1 expression positivity and response 
to nivolumab was published.36 However, in another Phase I 
study of safety and efficacy of nivolumab with a vaccine 
in ipilimumab-refractory or ipilimumab-naïve melanoma 
patients, patients with PD-L1-negative tumors also experi-
enced objective responses. These data indicate that a lack 
of expression of PD-L1 by the tumor does not preclude 
response to nivolumab.38 In addition, the Phase I trial of the 
combination of nivolumab and ipilimumab also evaluated 
the relationship between PD-L1 expression and response. In 
this study, PD-L1 positivity did not associate with improved 
responses to PD-1 therapy (ORR was noted in 6/13 PD-L1-
positive and 9/22 PD-L1-negative patients).39
PD-L1 is an inducible biomarker, and it cannot be con-
sidered in the same way as other molecular biomarkers in 
oncology, such as the presence of the estrogen receptor or 
human epidermal growth factor receptor (HER)-2 positiv-
ity in breast cancer or the epidermal growth factor receptor 
(EGFR) mutation in NSCLC. Varied assays are available to 
detect PD-L1 with immunohistochemistry using numerous 
antibodies, some of which stain tumor cells and others that 
stain additional cells in the tumor microenvironment. The 
precise cutoffs to determine ‘positivity’ are also not yet 
known.
In summary, though PD-L1 positivity may indicate an 
immune active tumor microenvironment that is favorable to 
PD-1 therapies, this requires further study. Since patients 
who lack PD-L1 expression may still benefit from anti-PD-1 
and anti-PD-L1 therapy, at this time we do not suggest 
excluding PD-L1-negative patients from clinical trials of 
these agents.13,36,53
Conclusion and future directions
A greater understanding of immune checkpoint inhibition 
has led to the discovery of efficacious immunotherapy 
approaches for patients with a variety of cancers. Therapies 
targeting CTLA-4, such as ipilimumab, have been the pro-
totypic immune checkpoint inhibitors and have paved the 
way for perhaps even more efficacious anti-PD-1 and anti-
PD-L1 antibodies. Clinical trials are demonstrating that these 
agents have benefit in many solid as well as hematologic 
malignancies.
The goal with immunotherapy is immune modulation and 
restoration of immune function, and the focus of treatment 
has shifted from targeting the tumor to targeting the patient’s 
immune system. Further research into optimal biomark-
ers, combination therapies with novel agents, and/or other 
immunotherapeutic agents, strategies for sequential therapies, 
optimal dosing, and duration of treatment is needed.Pharmacogenomics and Personalized Medicine 2014:7 submit your manuscript | www.dovepress.com
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